LA BioMed closes $50M bond sale to finance biotech research lab

LA BioMed is planning to open a new $63 milion, four-story bioscience research and incubator in February 2019. (Getty/choness)

LA BioMed—a nonprofit research organization located on the campus of Harbor-UCLA Medical Center campus—closed a $50 million bond sale to benefit a new biomedical research building and biotech incubator.

The sale of the Series 2018 Tax-Exempt Revenue Bonds, issued by the California Health Facilities Financing Authority, was led by Wells Fargo Securities. 

“The proceeds will help us create new innovative biomedical solutions with a new research building, biotech incubator and a campus that facilitates the bed-to-bench-to bed cycle of innovation we have nurtured at LA BioMed," said Dr. David Meyer, president and CEO of LA BioMed.

Webinar This Week

Optimizing Healthcare Operational Excellence to Drive Care Transformation

Join us in this webinar to learn how organizations have leveraged modern technology to enable transformative innovation and continuous improvement across their operations resulting in overall cost savings, process optimization, and clinical improvements.

RELATED: High ICU use increases costs, number of invasive procedures

LA BioMed is planning to open a new $63 million, four-story bioscience research and incubator in February 2019. It will be focused on improving healthcare through the research and development of new treatments and therapies and will offer space to incubate between 25 and 30 companies, officials said.

LA BioMed has launched 13 spin-offs since it launched in 2006. It is affiliated with the David Geffen School of Medicine at UCLA.

RELATEDHow some major health systems are overcoming the barriers to launching precision medicine programs

While academic health centers have always invested in tech transfer activities, they have increasingly poured investments into upgrading their biomedical research and their incubation spaces for commercialization in recent years. In July, RWJBarnabas Health announced a $1 billion partnership with Rutgers University as part of a bigger public-private partnership to create a jointly operated academic health system, including the construction of a new clinical and research building for the Rutgers Cancer Institute of New Jersey.

In April, Nashville-based Vanderbuilt University Medical Canter announced it would launch a subsidiary that will help commercialize its researchers' work with outside drug companies and Falls Church, Virginia-based Inova Health System, which is creating a personalized health campus, started both an accelerator and a drug discovery program as part of a vision to enhance research partnerships and creating new revenue streams.

Suggested Articles

Year by year, resistance to extending Medicaid to more low-income Americans in conservative states has given way.

Though a Medicare buy-in plan would likely lower costs for older adults, it could lead to higher premiums for younger people in the exchanges.

The AMA has adopted a new policy that calls on medical schools to incorporate additional training on health economics into their curricula.